Cyclophosphamide alters the clinical and pathological expression of experimental autoimmune gray matter disease

J. Tajti, Enrico Stefani, Stanley H. Appel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Guinea pigs inoculated with bovine spinal cord ventral horn homogenate develop a syndrome termed experimental autoimmune gray matter disease (EAGMD) characterized by extremity weakness, bulbar signs, and a loss of lower and upper motoneurons. To provide evidence for the role of autoimmune mechanisms, we have administered the immunosuppresant cyclophosphamide prior to and after gray matter immunization. Pretreatment with cyclophosphamide prevented the appearance of clinical signs of disease and decreased the loss of spinal cord motoneurons, the appearance of damaged motoneurons, and the antibody titer to motoneurons. Treatment 7 days after immunization attenuated the expression of disease. Treatment immediately after signs also improved the clinical and pathological findings. In all cyclophosphamide-treated animals there was less IgG within motoneurons and less inflammation. These results support the role for autoimmune mechanisms in motoneuron loss and degeneration in EAGMD.

Original languageEnglish
Pages (from-to)143-151
Number of pages9
JournalJournal of Neuroimmunology
Volume34
Issue number2-3
DOIs
Publication statusPublished - 1991

Fingerprint

Motor Neurons
Cyclophosphamide
Immunization
Gray Matter
Spinal Cord
Guinea Pigs
Extremities
Immunoglobulin G
Inflammation
Antibodies
Therapeutics

Keywords

  • (Guinea pig)
  • Cyclophosphamide
  • immune-mediated
  • Motoneuron destruction

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology

Cite this

Cyclophosphamide alters the clinical and pathological expression of experimental autoimmune gray matter disease. / Tajti, J.; Stefani, Enrico; Appel, Stanley H.

In: Journal of Neuroimmunology, Vol. 34, No. 2-3, 1991, p. 143-151.

Research output: Contribution to journalArticle

@article{2b4996fa1b5d4d38af0c1109d05845b0,
title = "Cyclophosphamide alters the clinical and pathological expression of experimental autoimmune gray matter disease",
abstract = "Guinea pigs inoculated with bovine spinal cord ventral horn homogenate develop a syndrome termed experimental autoimmune gray matter disease (EAGMD) characterized by extremity weakness, bulbar signs, and a loss of lower and upper motoneurons. To provide evidence for the role of autoimmune mechanisms, we have administered the immunosuppresant cyclophosphamide prior to and after gray matter immunization. Pretreatment with cyclophosphamide prevented the appearance of clinical signs of disease and decreased the loss of spinal cord motoneurons, the appearance of damaged motoneurons, and the antibody titer to motoneurons. Treatment 7 days after immunization attenuated the expression of disease. Treatment immediately after signs also improved the clinical and pathological findings. In all cyclophosphamide-treated animals there was less IgG within motoneurons and less inflammation. These results support the role for autoimmune mechanisms in motoneuron loss and degeneration in EAGMD.",
keywords = "(Guinea pig), Cyclophosphamide, immune-mediated, Motoneuron destruction",
author = "J. Tajti and Enrico Stefani and Appel, {Stanley H.}",
year = "1991",
doi = "10.1016/0165-5728(91)90123-O",
language = "English",
volume = "34",
pages = "143--151",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Cyclophosphamide alters the clinical and pathological expression of experimental autoimmune gray matter disease

AU - Tajti, J.

AU - Stefani, Enrico

AU - Appel, Stanley H.

PY - 1991

Y1 - 1991

N2 - Guinea pigs inoculated with bovine spinal cord ventral horn homogenate develop a syndrome termed experimental autoimmune gray matter disease (EAGMD) characterized by extremity weakness, bulbar signs, and a loss of lower and upper motoneurons. To provide evidence for the role of autoimmune mechanisms, we have administered the immunosuppresant cyclophosphamide prior to and after gray matter immunization. Pretreatment with cyclophosphamide prevented the appearance of clinical signs of disease and decreased the loss of spinal cord motoneurons, the appearance of damaged motoneurons, and the antibody titer to motoneurons. Treatment 7 days after immunization attenuated the expression of disease. Treatment immediately after signs also improved the clinical and pathological findings. In all cyclophosphamide-treated animals there was less IgG within motoneurons and less inflammation. These results support the role for autoimmune mechanisms in motoneuron loss and degeneration in EAGMD.

AB - Guinea pigs inoculated with bovine spinal cord ventral horn homogenate develop a syndrome termed experimental autoimmune gray matter disease (EAGMD) characterized by extremity weakness, bulbar signs, and a loss of lower and upper motoneurons. To provide evidence for the role of autoimmune mechanisms, we have administered the immunosuppresant cyclophosphamide prior to and after gray matter immunization. Pretreatment with cyclophosphamide prevented the appearance of clinical signs of disease and decreased the loss of spinal cord motoneurons, the appearance of damaged motoneurons, and the antibody titer to motoneurons. Treatment 7 days after immunization attenuated the expression of disease. Treatment immediately after signs also improved the clinical and pathological findings. In all cyclophosphamide-treated animals there was less IgG within motoneurons and less inflammation. These results support the role for autoimmune mechanisms in motoneuron loss and degeneration in EAGMD.

KW - (Guinea pig)

KW - Cyclophosphamide

KW - immune-mediated

KW - Motoneuron destruction

UR - http://www.scopus.com/inward/record.url?scp=0025999080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025999080&partnerID=8YFLogxK

U2 - 10.1016/0165-5728(91)90123-O

DO - 10.1016/0165-5728(91)90123-O

M3 - Article

VL - 34

SP - 143

EP - 151

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2-3

ER -